Recce Pharmaceuticals announced Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd (ASX: RCE) has provided an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

• Successful Phase Ia 1-hour single dose I.V. study proved R327 to be safe and well tolerated when administered over 60 healthy male adult volunteers. Thus, paving way for a Phase Ib/IIa multi-dose and early-stage sepsis efficacy study.
• Clinical data from the continuing Phase I (I.V.) clinical trial showed high concentrations of R327 present in urine in the bladder of healthy volunteers. This insight is in line with pre-clinical in-vivo kidney and UTI bacterial infection studies and supports primary excretion via the urine. Thus, suggesting prospects for therapeutic activity in the human urinary tract.
• Building upon success of the continuing topical burn wound infection program, RCE has built its topical broad-spectrum bacterial infection treatment programs, via the design of a new Phase II clinical study for Diabetic Foot Ulcer infections at a leading Australian teaching hospital. The clinical trial will evaluate R327 as a spray-on broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot ulcers. The first patient dosing is anticipated in Q4 2022.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au